Bio-Connect

AKR1B10 antibody [N3C3]

Research Use Only
GTX116651
GeneTex
ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry
Product group Antibodies
ReactivityHuman
TargetAKR1B10
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    AKR1B10 antibody [N3C3]
  • Delivery Days Customer
    9
  • Antibody Specificity
    Knockdown/Knockout validation was supported by customer review data.
  • Application Supplier Note
    WB: 1:500-1:3000. ICC/IF: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    ImmunoFluorescence, Western Blot, ImmunoCytoChemistry
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    0.34 mg/ml
  • Conjugate
    Unconjugated
  • Formulation
    Liquid
  • Gene ID57016
  • Target name
    AKR1B10
  • Target description
    aldo-keto reductase family 1 member B10
  • Target synonyms
    AKR1B11; AKR1B12; aldo-keto reductase family 1 member B10; aldo-keto reductase family 1, member B10 (aldose reductase); aldo-keto reductase family 1, member B11 (aldose reductase-like); aldose reductase-like 1; aldose reductase-like peptide; aldose reductase-related protein; ALDRLn; ARL1; ARL-1; ARP; hARP; HIS; HSI; SI reductase; small intestine reductase
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDO60218
  • Protein Name
    Aldo-keto reductase family 1 member B10
  • Scientific Description
    This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. This member can efficiently reduce aliphatic and aromatic aldehydes, and it is less active on hexoses. It is highly expressed in adrenal gland, small intestine, and colon, and may play an important role in liver carcinogenesis. [provided by RefSeq]
  • Reactivity
    Human
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer. Choi EJ et al., 2017 Sep 14, Oncogene
    Read more